Pfizer Inc. (NYSE:PFE) Shares Sold by FLC Capital Advisors

FLC Capital Advisors decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 27.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,350 shares of the biopharmaceutical company’s stock after selling 12,907 shares during the quarter. FLC Capital Advisors’ holdings in Pfizer were worth $989,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Worth Asset Management LLC bought a new position in Pfizer in the 1st quarter worth about $29,000. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the third quarter valued at approximately $30,000. GoalVest Advisory LLC boosted its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer in the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PFE shares. Barclays cut their target price on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. UBS Group cut their target price on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Friday, March 1st. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.18 during trading hours on Wednesday, reaching $27.77. The stock had a trading volume of 34,187,438 shares, compared to its average volume of 43,897,863. The business’s fifty day moving average is $27.47 and its two-hundred day moving average is $29.47. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22. The company has a market cap of $157.25 billion, a price-to-earnings ratio of 77.17, a PEG ratio of 1.23 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.14 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.